

Alessandra Ferrario

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3148260/publications.pdf>

Version: 2024-02-01

28
papers

1,021
citations

567281

15
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

1206
citing authors

#	ARTICLE	IF	CITATIONS
1	Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. <i>Social Science and Medicine</i> , 2015, 124, 39-47.	3.8	126
2	How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 307-321.	2.1	111
3	The economic burden of diabetes in India: a review of the literature. <i>Globalization and Health</i> , 2014, 10, 80.	4.9	108
4	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018, 6, 328.	2.7	102
5	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. <i>Pharmacoeconomics</i> , 2017, 35, 1271-1285.	3.3	94
6	Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs. <i>Health Affairs</i> , 2013, 32, 753-761.	5.2	82
7	Dabigatran â€“ a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. <i>Frontiers in Pharmacology</i> , 2013, 4, 39.	3.5	75
8	Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements. <i>Global Policy</i> , 2017, 8, 84-92.	1.7	46
9	Challenges in diabetes mellitus type 2 management in Nepal: a literature review. <i>Global Health Action</i> , 2016, 9, 31704.	1.9	35
10	Global access to quality-assured medical products: the Oxford Statement and call to action. <i>The Lancet Global Health</i> , 2019, 7, e1609-e1611.	6.3	32
11	Proposal for a regulation on health technology assessment in Europe â€“ opinions of policy makers, payers and academics from the field of HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 251-261.	1.4	31
12	Strategies to achieve fairer prices for generic and biosimilar medicines. <i>BMJ</i> , The, 2020, 368, l5444.	6.0	31
13	Diabetes in Algeria and challenges for health policy: a literature review of prevalence, cost, management and outcomes of diabetes and its complications. <i>Globalization and Health</i> , 2014, 10, 11.	4.9	29
14	Time to Entry for New Cancer Medicines: From European Unionâ€™Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden. <i>Value in Health</i> , 2018, 21, 809-821.	0.3	20
15	Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 9.	2.4	16
16	Medicines dispensers' knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. <i>Journal of Pharmaceutical Health Services Research</i> , 2017, 8, 227-233.	0.6	11
17	Clinical and Financial Implications of Medicine Consumption Patterns at a Leading Referral Hospital in Kenya to Guide Future Planning of Care. <i>Frontiers in Pharmacology</i> , 2018, 9, 1348.	3.5	11
18	The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists. <i>BMJ Global Health</i> , 2019, 4, e001681.	4.7	11

#	ARTICLE	IF	CITATIONS
19	Progress in increasing affordability of medicines for non-communicable diseases since the introduction of mandatory health insurance in the Republic of Moldova. <i>Health Policy and Planning</i> , 2016, 31, 793-800.	2.7	9
20	Strategic procurement and international collaboration to improve access to medicines. <i>Bulletin of the World Health Organization</i> , 2017, 95, 720-722.	3.3	9
21	An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. <i>Journal of Pharmaceutical Policy and Practice</i> , 2014, 7, 4.	2.4	8
22	Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand. <i>Bulletin of the World Health Organization</i> , 2020, 98, 467-474.	3.3	7
23	Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016. <i>JCO Oncology Practice</i> , 2022, 18, e677-e687.	2.9	5
24	Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States. <i>JCO Oncology Practice</i> , 2021, 17, e194-e203.	2.9	3
25	Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden. <i>European Journal of Health Economics</i> , 2017, 18, 1095-1105.	2.8	2
26	Availability and affordability of medicines: towards an evidence base for routine assessment. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 759-761.	11.4	2
27	What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool. <i>BMJ Open</i> , 2020, 10, e041901.	1.9	2
28	What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool. <i>BMJ Open</i> , 2020, 10, e041901.	1.9	0